Skip to content

To Compare Postoperative Horizontal Position Stability of the CT LUCIA 611P and the CT ASPHINA 409MP

Prospective Clinical Trial to Compare the Postoperative Horizontal Position Stability of the CT LUCIA 611P and the CT ASPHINA 409MP

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04036149
Enrollment
54
Registered
2019-07-29
Start date
2017-03-14
Completion date
2018-07-20
Last updated
2019-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract Senile

Brief summary

The main objective of the trial is to assess the efficacy of the CT LUCIA 611P intraocular lens (IOL) with regard to the horizontal IOL position stability. The horizontal position collected at 1 month and 4 to 6 months post-operatively will be compared to the horizontal IOL position recorded at baseline (1 week post-operatively) as well as to the position stability of the reference IOL, CT ASPHINA 409MP.

Interventions

DEVICEIntraocular lens

Implantation as part of cataract surgery

Sponsors

Carl Zeiss Meditec AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent; * Patients of any gender, aged 50 to 90 years; * Assured follow-up examinations; * Healthy eyes besides clinically significant bilateral age-related cataract. * Distance corrected visual acuity ≤ 0.3 logMAR Normal findings in the medical history and physical examination * Calculated IOL power within the available dioptre range; * Biometry measurement/cataract density compatible with the IOLMaster evaluation. Per operative inclusion criteria: * IOL implanted in the capsular bag; * The 2 IOL models (CT LUCIA 611P and CT ASPHINA 409MP) have been implanted in the 2 eyes of one patient; * No intraoperative complications; no damaged capsular bag, no intraocular haemorrhage; no can opener rhexis.

Exclusion criteria

* Allergy to heparin * Monophthalmic patient * Ocular disorders, other than cataract, that could potentially cause future acuity loss to a level of 0.20 logMAR (best-corrected) or worse in either eye; * Any anterior segment pathology that could significantly affect outcomes (e.g. chronic uveitis, iritis, corneal dystrophy, etc.); * Floppy iris syndrome; * Diabetic retinopathy; * Traumatic cataract; * Aniridia; * Microphthalmus; * Amblyopia; * Degenerative visual disorders (e.g. macular degeneration, optic nerve atrophy, or retinal disorders); * Patient expected to require retinal laser treatment before the end of the last follow-up; * Previous intraocular and corneal surgery; * Expected postop. astigmatism greater than 1 D; * Any type of corneal disorder; * Dementia; * Pseudoexfoliation syndrome (PEX); * Glaucoma or IOP higher than 24mmHg under ocular hypertension treatment; * Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient. * Pregnancy and/or lactation

Design outcomes

Primary

MeasureTime frameDescription
Horizontal position stability1 week to 4-6 months post-operativelyEvaluation of the horizontal position stability of the CT LUCIA 611P IOL. The horizontal position at M1 and M4-6 will be compared to the horizontal IOL position at baseline (W1) and to the position stability of the reference IOL, CT ASPHINA 409MP.

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026